Analysts at StockNews.com started coverage on shares of Trevena (NASDAQ:TRVN – Get Free Report) in a research report issued to clients and investors on Saturday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
Trevena Price Performance
NASDAQ:TRVN opened at $4.01 on Friday. The firm has a market cap of $3.41 million, a PE ratio of -1.50 and a beta of 1.03. The firm has a 50 day simple moving average of $2.72 and a 200-day simple moving average of $1.20. Trevena has a 1-year low of $3.35 and a 1-year high of $25.75.
Trevena (NASDAQ:TRVN – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.36. The business had revenue of $0.33 million during the quarter.
Institutional Trading of Trevena
About Trevena
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.
Recommended Stories
- Five stocks we like better than Trevena
- Compound Interest and Why It Matters When Investing
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- How to Calculate Options Profits
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- What Is WallStreetBets and What Stocks Are They Targeting?
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.